Purinergic receptor P2X and purinergic receptor P2Y (P2X, P2Y)

Purinergic receptors of the P2X family are trimeric ligand-gated ion channels activated specifically by ATP, mediating rapid cation flux and excitatory responses in neurons, platelets, and immune cells[1][7]. P2Y receptors are G protein-coupled receptors (GPCRs) activated by a broad spectrum of nucleotides (ATP, ADP, UTP, UDP, UDP-glucose), coupling to diverse intracellular signaling pathways and mediating slower, modulatory effects[1][5][7]. Both families are widely expressed throughout the central and peripheral nervous systems and other tissues, contributing to neural transmission, inflammation, cell growth, and immune responses. There are at least seven P2X (P2X1–P2X7) and eight P2Y (P2Y1,2,4,6,11–14) receptor subtypes, each with distinct ligand preference and tissue distribution[2][7]. In disease, P2X and P2Y subtypes exhibit subtype-specific roles—e.g., P2Y12 is central for platelet aggregation, while P2X7 is implicated in neuroinflammation, pain, and cancer cell death[2][4][5]. Pharmacological targeting has led to major drugs for cardiovascular disease prevention (P2Y12 antagonists)[6]. Selective modulation remains a therapeutic challenge due to complex, overlapping signaling pathways and tissue-specific functions[5][8].

Other names

P2 receptors (collective family)ATP receptor (for P2X)Purinergic receptor, subtype X/Y

Antagonism of P2Y12 receptor to block ADP-induced platelet aggregation (antithrombotic) Agonism/antagonism of P2X and P2Y subtypes to modulate immune responses, cell proliferation, and pain signaling